PRESS-RELEASE ·Filed Apr 22, 2026

SUPN

Supernus Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release: earnings
Actionable Insight • Neutral

Monitor the May 5 earnings call for Q1 2026 results, particularly revenue and EPS relative to consensus. No immediate trading catalyst is present in this release.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
SUPN ▼ -5.89% at T+60d
NEUTRAL call ✗ call lost -5.89% · α vs SPY -10.91% · entry $50.39 → $47.42
Entry anchored
Apr 22, 03:59 PM ET
via exchange tick
T+1d
-1.25%
call -1.25% · α -2.04%
$49.76
settled 5mo ago
T+5d
-3.65%
call -3.65% · α -5.13%
$48.55
settled 5mo ago
T+20d
-3.37%
call -3.37% · α -8.01%
$48.69
settled 5mo ago
T+60d
-5.89%
call -5.89% · α -10.91%
$47.42
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Supernus Pharmaceuticals announced it will report Q1 2026 financial results on May 5, 2026, with a subsequent conference call. No actual financials were released in this press release — it is purely a scheduling notice.

Key Facts

  • Supernus Pharmaceuticals (SUPN) will report Q1 2026 financial results on May 5, 2026, after market close.
  • CEO Jack Khattar and CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss results.
  • No financial data or business updates were included in this release — it is an earnings announcement preview.
  • A webcast and replay will be available via the company’s Investor Relations website.

Financial Impact

No financial data disclosed

Risk Factors

  • Forward-looking statements are subject to risks including regulatory, commercial, and financial uncertainties.
  • No assurance that future profitability or revenue growth will be sustained.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3279414
20 reports for SUPN
Performance horizon
75% Hit rate 6 of 8 directional calls best @ T+1▲ +8.46%Aug 3, 2026
Filters
Rows
Reports for SUPN — sortable, filterable
TypeNow
Sep 11, 2026
20d ago
DEFM14A
MIXED ★ 7/10
$41.49 $42.78▲ +3.11%▲ +3.00%$42.60 (+2.68%)
Aug 3, 2026
8w ago
DEFA14A / 425
BULLISH ★ 7/10
$43.25 $46.88▲ +8.39%▲ +8.49%$42.60 (−1.50%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 7/10
$43.25 $46.88▲ +8.39%▲ +8.49%$42.60 (−1.50%)
Aug 3, 2026
8w ago
DEFA14A / 425
BULLISH ★ 8/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 7/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Aug 3, 2026
8w ago
8-K
MIXED ★ 7/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Aug 3, 2026
8w ago
DEFA14A / 425 / 8-K
BULLISH ★ 8/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Jul 22, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$47.19 $45.61▼ −3.35%▼ −3.82%$42.60 (−9.73%)
Jul 22, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$47.19 $45.61▼ −3.35%▼ −3.82%$42.60 (−9.73%)
Jul 20, 2026
10w ago
Court Ruling
NEUTRAL ★ 3/10
$47.42 $46.20▼ −2.57%▼ −2.15%$42.60 (−10.16%)
Showing 10 of 20

US Market Status

Market Open — Closes in 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 22, 2026